Forsyth, CA
Allyn Forsyth, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090215088 | Tagged Ligands For Enrichment of Rare Analytes From A Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 08-27-2009 |
20110300603 | Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 12-08-2011 |
20130260392 | TAGGED LIGANDS FOR ENRICHMENT OF RARE ANALYTES FROM A MIXED SAMPLE - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 10-03-2013 |
20140234986 | TAGGED LIGANDS FOR ENRICHMENT OF RARE ANALYTES FROM A MIXED SAMPLE - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 08-21-2014 |
Ben Forsyth, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20110145810 | METHOD IN A NETWORK OF THE DELIVERY OF FILES - A method in a network of the delivery of files from a server computer ( | 06-16-2011 |
David E. Forsyth, Laguna Beach, CA US
Patent application number | Description | Published |
---|---|---|
20090188501 | Self Contained Breathing Apparatus Modular Control System - The claim over prior art is for an approach to an electronically controlled or electronically monitored breathing system that represents an improvement in electrical reliability, manufacturing cost and efficiency, user maintenance, system reliability, user cost and maintenance. These improvements are accomplished by placing the major electronic, mechanical and electromechanical control elements and sensor components in a single replaceable module. | 07-30-2009 |
20130066564 | SYSTEM AND METHOD FOR DYNAMICALLY MEASURING OXYGEN LEVELS - An oxygen sensing system including an oxygen sensor, a microprocessor and one or more additional sensors for sensing parameters associated with the environment or with the oxygen sensor, accounts for one or more sensed conditions when calculating oxygen levels. The one or more sensors may sense conditions associated with environmental effects or effects of use that may cause the oxygen sensor to degrade over usage or over time. A baseline amplification and measurement circuit coupled to the oxygen sensor may enable the sensor to operate less frequently or for shorter periods of time, thereby increasing the life span, calibration hold time of the sensor, and reducing power requirements. | 03-14-2013 |
David Edward Forsyth, Laguna Beach, CA US
Patent application number | Description | Published |
---|---|---|
20120078532 | NON-DISPERSIVE INFRARED SENSOR MEASUREMENT SYSTEM AND METHOD - Non-dispersive infrared (NDIR) sensing systems employ a NDIR sensor coupled to a microprocessor to determine gas concentrations by employing slope-based methodologies that compensate for pressure variations, temperature variations, or both, which may compare NDIR signals with calibrated data. NDIR sensor systems may employ means for limiting the system peak current demand providing for the portability and scalability of the system. In NDIR sensor systems calculating gas concentrations using calibration data, the phase of the change in the NDIR output signal in response to a change in the infrared source emitter level may be measured as part of the calibration process. | 03-29-2012 |
Roger Allyn Forsyth, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20100120047 | PURIFICATION OF TARGET CELLS FROM COMPLEX BIOLOGICAL FLUIDS - A method for conducting a molecular analysis on target cells of a complex biological fluid can include the steps of reducing the complexity by selectively depleting at least a portion of non-target cells from the biological fluid, labeling target cells or non-target cells for identification, isolating target cells from non-target cells based on (i) a size, or (ii) a label, of the target cells or the non-target cells using a microfluidic sorting apparatus, and molecularly analyzing the target cells. Reducing can include separating the non-target cells from the biological fluid using a Magnetic Activated Cell Sorting apparatus or using magnetic beads that include a plurality of different antibodies including one or more of CD45, CD16 and 235a. Labeling can include using a label selected from fluorescent, colorimetric, magnetic and biochemical labels. The biological fluid can be selected from blood sputum, peritoneal fluid, tissue cell suspension, fine needle aspirates, fecal matter and cerebral spinal fluid. The target cells can be selected from tumor cells, fetal cells, stem cells, endothelial cells, myocardial cells and lymphocytes. The step of molecularly analyzing the target cells can include one of RNA analysis, antigen expression and mutation profiling. | 05-13-2010 |
20130017541 | Methods and Compositions for Segregating Target Nucleic Acid from Mixed Nucleic Acid Samples - The invention provides methods, compositions and kits for segregating a target nucleic acid from a mixed nucleic acid sample. The methods, compositions and kits comprise a non-processive endonuclease (e.g., a restriction enzyme) or an antibody that binds the target nucleic acid (e.g., has methylation specificity). The mixed nucleic acid sample can comprise prokaryotic and eukaryotic nucleic acid and/or nucleic acid from more than one prokaryotic or eukaryotic organisms. | 01-17-2013 |
20130337460 | Methods and Compositions for Segregating Target Nucleic Acid from Mixed Nucleic Acid Samples - The invention provides methods, compositions and kits for segregating a target nucleic acid from a mixed nucleic acid sample. The methods, compositions and kits comprise a non-processive endonuclease (e.g., a restriction enzyme) or an antibody that binds the target nucleic acid (e.g., has methylation specificity). The mixed nucleic acid sample can comprise prokaryotic and eukaryotic nucleic acid and/or nucleic acid from more than one prokaryotic or eukaryotic organisms. | 12-19-2013 |
Timothy Forsyth, Hayward, CA US
Patent application number | Description | Published |
---|---|---|
20100136136 | JAK-2 Modulators and Methods of Use - This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention. | 06-03-2010 |
Timothy P. Forsyth, Hayward, CA US
Patent application number | Description | Published |
---|---|---|
20140121125 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to | 05-01-2014 |
20140212898 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to | 07-31-2014 |
Timothy Patrick Forsyth, Hayward, CA US
Patent application number | Description | Published |
---|---|---|
20080234270 | Pyrrole Derivatives As Pharmaceutical Agents - Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors. | 09-25-2008 |
20080249079 | Pyrimidine Derivatives As Kinase Modulators and Method of Use - The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR | 10-09-2008 |
20090105211 | INHIBITORS OF HEDGEHOG PATHWAY - The present invention is directed to a compound of Formula I | 04-23-2009 |
20090105299 | c-MET MODULATORS AND METHODS OF USE - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 04-23-2009 |
20090170896 | c-Met modulators and methods of use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 07-02-2009 |
20090298830 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use - This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R | 12-03-2009 |
20110077233 | C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 03-31-2011 |
20110201599 | CDK Modulators - A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof. | 08-18-2011 |
20110301128 | Pyrrole Derivatives As Pharmaceutical Agents - Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors. | 12-08-2011 |
20120022065 | C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 01-26-2012 |
20120070368 | Methods of Using C-Met Modulators - Disclosed are methods of treating cancer by administering a compound of Formula I, | 03-22-2012 |
20120184523 | C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 07-19-2012 |
20120238570 | INHIBITORS OF THE HEDGEHOG PATHWAY - The present invention is directed to a compound of Formula I | 09-20-2012 |
20120245139 | INHIBITORS OF THE HEDGEHOG PATHWAY - The present invention is directed to a compound of Formula I | 09-27-2012 |
20130252940 | c-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 09-26-2013 |
20140155378 | c-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 06-05-2014 |
20140155396 | C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 06-05-2014 |